PedAM
Pediatric Disease Annotations & Medicines
| cluster headache | ||||
| Disease ID | 514 |
|---|---|
| Disease | cluster headache |
| Definition | A primary headache disorder that is characterized by severe, strictly unilateral PAIN which is orbital, supraorbital, temporal or in any combination of these sites, lasting 15-180 min. occurring 1 to 8 times a day. The attacks are associated with one or more of the following, all of which are ipsilateral: conjunctival injection, lacrimation, nasal congestion, rhinorrhea, facial SWEATING, eyelid EDEMA, and miosis. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1) |
| Synonym | bing-horton syndrome cephalalgia, histamine cephalalgia, paroxysmal, nocturnal, orbital cephalgia, histamine cephalgias, histamine chronic cluster headache chronic cluster headache (disorder) chronic cluster headaches ciliary neuralgia ciliary neuralgia (disorder) ciliary neuralgias cluster headache (disorder) cluster headache (disorder) [ambiguous] cluster headache [disease/finding] cluster headache nos cluster headache syn nos cluster headache syndrome cluster headache syndrome (disorder) cluster headache syndrome, unspecified cluster headache syndromes cluster headache, chronic cluster headaches cluster headaches, chronic clusters headache erythroprosopalgia headache cluster headache histamine headache syndrome, cluster headache syndromes, cluster headache vasomotor headache, chronic cluster headache, cluster headaches cluster headaches histamine headaches, chronic cluster headaches, cluster histamine cephalgia histamine cephalgias histamine headache horton syndrome horton's headache horton's neuralgia horton's syndrome hortons syndrome migraine, neuralgic migraines, neuralgic migrainous neuralgia neuralgia, ciliary neuralgias, ciliary neuralgic migraine neuralgic migraines syndrome, cluster headache syndrome, horton syndrome, horton's syndromes, cluster headache vasomotor headache |
| UMLS | C0009088 |
| MeSH | |
| SNOMED-CT | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:11) C0149931 | migraine | 2 C0851578 | sleep disorders | 1 C0338078 | non-functioning pituitary adenoma | 1 C0271355 | sixth nerve palsy | 1 C0005745 | ptosis | 1 C0037315 | sleep apnea syndrome | 1 C0008698 | maxillary sinusitis | 1 C0155804 | acute maxillary sinusitis | 1 C0035460 | vasomotor rhinitis | 1 C0037315 | sleep apnea | 1 C0854486 | functioning pituitary adenoma | 1 |
| Curated Gene | (Waiting for update.) |
| Inferring Gene | Entrez_id | Symbol | Resource(Total Genes:7) |
| Text Mined Gene | (Waiting for update.) |
| Locus | (Waiting for update.) |
| Disease ID | 514 |
|---|---|
| Disease | cluster headache |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:13) HP:0012531 | Pain | 4 HP:0002076 | Migraine headaches | 2 HP:0002104 | Absence of spontaneous respiration | 1 HP:0100022 | Movement disorder | 1 HP:0012533 | Allodynia | 1 HP:0010535 | Sleep apnea | 1 HP:0012342 | Macroprolactinoma | 1 HP:0005294 | Arterial dissection | 1 HP:0012286 | Abnormal hypothalamus morphology | 1 HP:0011349 | Sixth nerve palsy | 1 HP:0000508 | Drooping upper eyelid | 1 HP:0002183 | Fear of loud sounds | 1 HP:0001269 | Hemiparesis | 1 |
| Disease ID | 514 |
|---|---|
| Disease | cluster headache |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:15) C2598155 | pain C1963237 | insomnia C1963138 | hypertension C1707516 | corneal sensitivity C0751466 | phonophobia C0393593 | dystonia C0376480 | gingival enlargement C0271355 | vi nerve palsy C0184567 | acute pain C0149931 | migraine C0042769 | viral infection C0037763 | spasm C0037315 | sleep disordered breathing C0037315 | sleep apnea C0019937 | horner's syndrome |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:4) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1800562 | 12100096 | 3077 | HFE | umls:C0009088 | BeFree | A 60-year-old woman with secondary chronic cluster headache had increased serum ferritin and serum transferrin saturation and was homozygous for the C282Y mutation in the HFE gene, which is indicative of hereditary haemochromatosis. | 0.002909916 | 2002 | HFE | 6 | 26092913 | G | A |
| rs1801133 | 20946434 | 4524 | MTHFR | umls:C0009088 | BeFree | An association between the 677C>T polymorphism (rs1801133) in the methylenetetrahydrofolate reductase gene (MTHFR) and cluster headache is plausible, but has not been investigated. | 0.000271442 | 2011 | MTHFR | 1 | 11796321 | G | A |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:1) | ||||
|---|---|---|---|---|
| HP ID | HP Name | MP ID | MP Name | Annotation |
| HP:0000822 | Hypertension | MP:0011250 | abdominal situs ambiguus;HP:0012531 | Pain |
Chemical(Total Drugs:3) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0009088 | indomethacin | D007213 | 53-86-1 | cluster headache | MESH:D003027 | therapeutic | 16601942 | ||
| C0009088 | octreotide | D015282 | 83150-76-9 | cluster headache | MESH:D003027 | therapeutic | 11398310 | ||
| C0009088 | topiramate | C052342 | 97240-79-4 | cluster headache | MESH:D003027 | therapeutic | 15928910 | ||
FDA approved drug and dosage information(Total Drugs:8) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D003027 | topamax | topiramate | 100MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
| MESH:D003027 | topamax | topiramate | 15MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D003027 | topamax | topiramate | 100MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
| MESH:D003027 | topamax | topiramate | 15MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D003027 | topamax | topiramate | 100MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
| MESH:D003027 | topamax | topiramate | 15MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D003027 | topamax | topiramate | 100MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
| MESH:D003027 | topamax | topiramate | 15MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
FDA labeling changes(Total Drugs:8) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D003027 | 12/22/2009 | topamax | topiramate | Migraine Prophylaxis | Safety and effectiveness for migraine prevention in pediatric patients have not been established Dose-related increased shift in serum creatinine in adolescent patients occurred in a clinical study Information added to Warnings and Precautions and Pediatric Use | Labeling | - | P | - | - | Ortho-McNeil-Janssen | - | FALSE' |
| MESH:D003027 | 12/22/2009 | topamax | topiramate | Migraine Prophylaxis | Safety and effectiveness for migraine prevention in pediatric patients have not been established Dose-related increased shift in serum creatinine in adolescent patients occurred in a clinical study Information added to Warnings and Precautions and Pediatric Use | Labeling | - | P | - | - | Ortho-McNeil-Janssen | - | FALSE' |
| MESH:D003027 | 12/22/2009 | topamax | topiramate | Adjunctive Treatment for Partial Onset Epilepsy in Infants and Toddlers 1 to 24 months | Effectiveness was not demonstrated as adjunctive therapy in a randomized, double-blind trial in infants/toddlers 1 to 24 months of age with refractory partial onset seizures Trials in infants/toddlers 1 to 24 months suggested some adverse reactions/toxicities not previously observed in older pediatric patients and adults; i.e, growth/length retardation, certain clinical laboratory abnormalities, and other adverse reactions/toxicities that occurred with a greater frequency and/or greater severity than had been recognized previously from studies in older pediatric patients or adults for various indications. Information added to Warnings and Precautions and Pediatric Use | Labeling | B | - | - | - | Ortho-McNeil-Janssen | 07/24/2008 | FALSE' |
| MESH:D003027 | 12/22/2009 | topamax | topiramate | Adjunctive Treatment for Partial Onset Epilepsy in Infants and Toddlers 1 to 24 months | Effectiveness was not demonstrated as adjunctive therapy in a randomized, double-blind trial in infants/toddlers 1 to 24 months of age with refractory partial onset seizures Trials in infants/toddlers 1 to 24 months suggested some adverse reactions/toxicities not previously observed in older pediatric patients and adults; i.e, growth/length retardation, certain clinical laboratory abnormalities, and other adverse reactions/toxicities that occurred with a greater frequency and/or greater severity than had been recognized previously from studies in older pediatric patients or adults for various indications. Information added to Warnings and Precautions and Pediatric Use | Labeling | B | - | - | - | Ortho-McNeil-Janssen | 07/24/2008 | FALSE' |
| MESH:D003027 | 07/15/2011 | topamax | topiramate | Monotherapy for partial onset or primary generalized tonic-clonic seizures | Expanded age range down to 2 years; previously approved for monotherapy for partial onset or primary generalized tonic-clonic seizures in patients10 years and older Information on weight based dosing in 2 to < 10 yearsPostmarketing study | Labeling | - | P | - | - | Janssen | - | FALSE' |
| MESH:D003027 | 07/15/2011 | topamax | topiramate | Monotherapy for partial onset or primary generalized tonic-clonic seizures | Expanded age range down to 2 years; previously approved for monotherapy for partial onset or primary generalized tonic-clonic seizures in patients10 years and older Information on weight based dosing in 2 to < 10 yearsPostmarketing study | Labeling | - | P | - | - | Janssen | - | FALSE' |
| MESH:D003027 | 03/28/2014 | topamax | topiramate | Prophylaxis of migraine headache | Approved for use in pediatric patients 12 years and older Safety and effectiveness in pediatric patients less than12 years have not been established for the prophylaxis treatment of migraine headache In the adolescent migraine trials (12 to 17 years), the most commonly observed adverse reactions were: paresthesia, upper respiratory tract infection, anorexia, and abdominal pain The most common cognitive adverse reaction in pooled double-blind studies in adolescent patients 12 to 17 years was difficulty with concentration/attention Markedly abnormally low serum bicarbonate values indicative of metabolic acidosis were reported in topiramate-treated adolescent migraine patients In topiramate-treated patients 12 to 17 years compared to placebo-treated patients, abnormally increased results were more frequent for creatinine, BUN, uric acid, chloride, ammonia, total protein, and platelets. Abnormally decreased results were observed with topiramate vs placebo treatment for phosphorus and bicarbonate Notable changes (increases and decreases) from baseline in systolic blood pressure, diastolic blood pressure, and pulse were observed more commonly in adolescents treated with topiramate compared to adolescents treated with placebo Information on dosing, adverse reactions, laboratory abnormalities, and clinical trials Postmarketing study | Labeling | - | P | - | - | Janssen | - | FALSE' |
| MESH:D003027 | 03/28/2014 | topamax | topiramate | Prophylaxis of migraine headache | Approved for use in pediatric patients 12 years and older Safety and effectiveness in pediatric patients less than12 years have not been established for the prophylaxis treatment of migraine headache In the adolescent migraine trials (12 to 17 years), the most commonly observed adverse reactions were: paresthesia, upper respiratory tract infection, anorexia, and abdominal pain The most common cognitive adverse reaction in pooled double-blind studies in adolescent patients 12 to 17 years was difficulty with concentration/attention Markedly abnormally low serum bicarbonate values indicative of metabolic acidosis were reported in topiramate-treated adolescent migraine patients In topiramate-treated patients 12 to 17 years compared to placebo-treated patients, abnormally increased results were more frequent for creatinine, BUN, uric acid, chloride, ammonia, total protein, and platelets. Abnormally decreased results were observed with topiramate vs placebo treatment for phosphorus and bicarbonate Notable changes (increases and decreases) from baseline in systolic blood pressure, diastolic blood pressure, and pulse were observed more commonly in adolescents treated with topiramate compared to adolescents treated with placebo Information on dosing, adverse reactions, laboratory abnormalities, and clinical trials Postmarketing study | Labeling | - | P | - | - | Janssen | - | FALSE' |